A carregar...
Sodium orthovanadate overcomes sorafenib resistance of hepatocellular carcinoma cells by inhibiting Na(+)/K(+)-ATPase activity and hypoxia-inducible pathways
The resistance to sorafenib highly affects its clinical benefits for treating hepatocellular carcinoma (HCC). Sodium orthovanadate (SOV) is a phosphate analog that displays anti-cancer activities against various types of malignancies including HCC. The present study has demonstrated that SOV is able...
Na minha lista:
| Publicado no: | Sci Rep |
|---|---|
| Main Authors: | , , , , , , , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
Nature Publishing Group UK
2018
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6018801/ https://ncbi.nlm.nih.gov/pubmed/29946188 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/s41598-018-28010-y |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|